-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Aardvark Therapeutics, Lowers Price Target to $21

Benzinga·03/02/2026 14:59:00
Listen to the news
Oppenheimer analyst Leland Gershell maintains Aardvark Therapeutics (NASDAQ:AARD) with a Outperform and lowers the price target from $35 to $21.